- Home
- FGEN vs DARE Comparison
FGEN vs DARE Comparison
Compare FGEN & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- DARE
- Stock Information
- Founded
- FGEN 1993
- DARE 2015
- Country
- FGEN United States
- DARE United States
- Employees
- FGEN N/A
- DARE N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- DARE Health Care
- Exchange
- FGEN Nasdaq
- DARE Nasdaq
- Market Cap
- FGEN 33.5M
- DARE 26.3M
- IPO Year
- FGEN 2014
- DARE N/A
- Fundamental
- Price
- FGEN $5.85
- DARE $2.44
- Analyst Decision
- FGEN Strong Buy
- DARE Strong Buy
- Analyst Count
- FGEN 1
- DARE 3
- Target Price
- FGEN $250.00
- DARE $12.50
- AVG Volume (30 Days)
- FGEN 61.5K
- DARE 38.9K
- Earning Date
- FGEN 08-05-2025
- DARE 08-11-2025
- Dividend Yield
- FGEN N/A
- DARE N/A
- EPS Growth
- FGEN N/A
- DARE N/A
- EPS
- FGEN N/A
- DARE N/A
- Revenue
- FGEN $6,996,000.00
- DARE $25,909.00
- Revenue This Year
- FGEN N/A
- DARE $99,756.91
- Revenue Next Year
- FGEN N/A
- DARE $119.77
- P/E Ratio
- FGEN N/A
- DARE N/A
- Revenue Growth
- FGEN N/A
- DARE N/A
- 52 Week Low
- FGEN $4.50
- DARE $2.35
- 52 Week High
- FGEN $38.25
- DARE $4.60
- Technical
- Relative Strength Index (RSI)
- FGEN 43.29
- DARE 35.15
- Support Level
- FGEN $5.37
- DARE $2.37
- Resistance Level
- FGEN $5.73
- DARE $2.54
- Average True Range (ATR)
- FGEN 0.41
- DARE 0.11
- MACD
- FGEN 0.07
- DARE -0.02
- Stochastic Oscillator
- FGEN 77.78
- DARE 17.50
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.